牛市里“挨揍”？林园19只产品全跑输沪深300，6 只还亏了

Core Insights - The performance of Lin Yuan's investment products has significantly lagged behind the CSI 300 index, with 19 products failing to outperform it, and 6 products recording losses year-to-date [1][2][3] - The current market trend shows a stark divergence, with technology sectors like AI, computing, and semiconductors leading, while traditional sectors such as liquor, real estate, and coal are underperforming [1][3] - Lin Yuan's long-term focus on consumer and pharmaceutical sectors has negatively impacted performance, as these sectors have shown weakness compared to the booming technology and cyclical sectors [3][5] Performance Analysis - As of September 29, the CSI 300 index has a year-to-date increase of 17.4%, while Lin Yuan's best-performing product, "Lin Yuan 218," achieved a return of only 31.14%, falling short of the index's 42.14% [1][2] - Among Lin Yuan's 19 products, only 9 have positive returns over the past year, while 10 have negative returns, indicating a significant underperformance [1][2] - Specific products like "Lin Yuan 173" have seen a decline of 24% since inception, contrasting sharply with the CSI 300's decline of only 5.35% during the same period [2][3] Market Strategy and Trends - Lin Yuan's recent investments in technology stocks have been described as "negligible," and the decision to invest in the STAR Market was largely driven by passive requirements rather than strategic choice [3][4] - The broader private equity landscape is experiencing a shift, with quantitative funds outperforming discretionary funds, highlighting a mismatch in strategy and market conditions for many traditional investment firms [4][5] - The performance disparity among private equity firms is attributed to their inability to adapt to the current market dynamics, particularly in capturing opportunities in technology and cyclical sectors [5]